Clinical trials: Obstructive Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy, Obstructive
Percutaneous Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy in Children
The primary purpose of this study was to demonstrate the safety and efficacy of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) in children and assessed its performance and functional outcomes in the…
- Trial name
- NCT06540183
- Testing
- Percutaneous intramyocardial septal radiofrequency ablation
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Xijing Hospital
Hypertrophic Obstructive Cardiomyopathy
Comparisonof Extended Myoectomy and Myoectomy by Morrow in Patients With Hypertrophic Obstructive Cardiomyopathy (HOCM)
The purpose of this study is to determine whether the application of the extended myoectomy in patients with obstruction of the left ventricular output more efficient than standard myoectomy by Morrow.
- Trial name
- NCT02492399
- Testing
- extended myectomy, myectomy by Morrow
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Hypertrophic Obstructive Cardiomyopathy
Residual or Recurrent Obstruction After Septal Myectomy
The goal of this observational study is to report the outcomes after septal myectomy in young children and infants and identify the mechanisms of residual or recurrent obstruction after surgery.
- Trial name
- NCT05687487
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Cardiomyopathy
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in adults diagnosed with symptomatic obstructive hypertrophic cardiomyopathy (HOCM) receiving cibenzoline in Japan
- Trial name
- NCT07541833
- Testing
- Mavacamten
- Where
- Japan
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Nonobstructive Hypertrophic Cardiomyopathy
Dapagliflozin in Patients With Non-Obstructive Hypertrophic Cardiomyopathy: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of dapagliflozin in patients with nonobstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- DAPA-HCM (NCT07897500)
- Testing
- Dapagliflozin 10mg
- Volunteers
- 440 people
- Sponsor
- Yonsei University
Obstructive Hypertrophic Cardiomyopathy
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.
- Trial name
- COMPASS-HCM (NCT06551129)
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Bristol-Myers Squibb
HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction
Reverse Remodeling After PTSMA in Severe But Asymptomatic LVOT Obstruction
Patients with HOCM and severe LVOT obstruction can remain asymptomatic while significant cellular and structural changes of the heart (adverse remodeling) may occur preceding heart failure and rhythm disorders.
- Conditions
- HOCM, Hypertrophic Obstructive Cardiomyopathy, LVOTO - Left Ventricular Outflow Tract Obstruction, Remodeling, Ventricular
- Trial name
- RASTA (NCT04230551)
- Testing
- PTSMA
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- St. Antonius Hospital
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Biological Collection for the Purpose of Exploring Genetic and Clinical-biological Factors Associated With Variability in Response to Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy
The European Medicines Agency has required pre-treatment genotyping of CYP2C19 to determine the initial and maximum dosage, in order to avoid overexposure to mavacamten associated with a decrease in ventricular ejection fraction…
- Trial name
- MAVA PG (NCT07439952)
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertrophic Cardiomyopathy
Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
Objective The objective of the study is to assess the structural and functional cardiac effects of treatment with losartan in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- INHERIT (NCT01447654)
- Testing
- Losartan
- Where
- Denmark
- Volunteers
- 130 people
- Sponsor
- Henning Bundgaard
Hypertrophic Obstructive Cardiomyopathy
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM) is an inherited myocardial disease which leads to the muscle in the wall of the heart growing and thickening to the point that it blocks blood flow exiting the heart with increasing…
- Trial name
- SELECT (NCT04686487)
- Testing
- stereotactic ablative radiotherapy
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Xiangya Hospital of Central South University
Hypertrophic Obstructive Cardiomyopathy (HOCM)
CArdiac Desynchronization In Obstructive HCM, CARDIO-HCM
The purpose of this study is to evaluate the benefit of the optimal pacing configuration, including the possibility of biventricular or left ventricular pacing, in hypertrophic obstructive cardiomyopathy patients.
- Trial name
- CARDIO-HCM (NCT01332162)
- Testing
- Biventricular pacing, No Pacing
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
Hypertrophic Cardiomyopathy
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by…
- Trial name
- MyPEAK-1 (NCT05836259)
- Testing
- TN-201
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tenaya Therapeutics
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
- Trial name
- NCT07383025
- Testing
- Mavacamten
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Obstructive Cardiomyopathy
Echocardiography-guided Transthoracic Radio Frequency/Laser Ablation for Ventricular Septum of Hypertrophic Obstructive Cardiomyopathy
Hypertrophic Obstructive Cardiomyopathy (HOCM) patients have significant clinical symptoms, including progressively increasing fatigue, angina, exertional dyspnea, and syncope.
- Trial name
- NCT02888132
- Testing
- Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum, Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xijing Hospital
Cardiomyopathy, Hypertrophic Obstructive
BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The main purpose of this trial is to find out whether BHB-1893 works better than metoprolol in adults with symptoms of obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- LIONHEART-HCM (NCT07755904)
- Testing
- BHB-1893, Metoprolol
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Braveheart Bio, Inc.
Hypertrophic Cardiomyopathy
Echocardiography-guided Percutaneous Septal Radiofrequency Ablation for Obstructive HCM After Alcohol Septal Ablation
After alcohol ablation, some HOCM patients have serious clinical symptoms and adverse complications, and need to undergo invasive surgery again when adequate drug therapy is not effective or cannot tolerate the side effects of…
- Trial name
- HCM (NCT06496633)
- Testing
- Percutaneous Intramyocardial Septal Radiofrequency Ablation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xijing Hospital
HCM - Hypertrophic Cardiomyopathy
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic…
- Trial name
- NCT07294495
- Testing
- Henagliflozin (SGLT2 Inhibitor)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai East Hospital
Cardiomyopathy, Hypertrophic
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT06253221
- Testing
- Mavacamten
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy, Obstructive
Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric hypertrophy of the heart in absence of loading conditions like hypertension.
- Trial name
- FUSION-HCM (NCT06400524)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have…
- Trial name
- NCT07807384
- Testing
- Mavacamten
- Volunteers
- 115 people
- Sponsor
- Second Affiliated Hospital of Nanchang University